The investments will support new product offerings, expansion in the US and the development of fundamental pathology models.
BERLIN and NEW YORK, Oct. 29, 2024 /PRNewswire/ — Aignostics, a global artificial intelligence (AI) company that transforms complex multimodal pathology data into transformative insights, today announced that it has raised $1,000 in Series B financing received $34 million. The additional funding will be used to build new product offerings for biopharmaceutical customers, drive growth in the United States (US), and develop leading-edge fundamental pathology models in collaboration with Mayo Clinic. The oversubscribed financing round was led by ATHOS with investment from Mayo Clinic and growth financing from HTGF, as well as support from existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund and the VC fund Technology managed by IBB Ventures. In total, Aignostics has now raised over $55 million, reflecting investor confidence in its differentiated AI models and clear business strategy.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to improve the utility, performance, and scalability of computational pathology analysis for drug development and diagnostics. In parallel, machine learning technologies are evolving rapidly, producing AI models with record-breaking accuracy and robustness, opening new avenues for biopharmaceutical research and diagnostics.
“At its core, Aignostics is a world-class machine learning company,” said Julian Zachmann of ATHOS. “The field is advancing so quickly that to succeed, AI companies avoid flashy distractions, focus on the highest quality science, and are relentless “Aignostics is doing just that, offering its biopharmaceutical customers a level of transparency and care that we believe is truly unique.”
“We know that digital pathology, coupled with the enormous possibilities of AI, has immense potential for diagnosing and treating patients. Mayo Clinic is actively exploring the new frontiers of predictive and personalized care,” said Jim Rogers, CEO of Mayo Clinic Digital Pathology.
The new funding will strengthen Aignostics’ Target ID, translational research and companion diagnostics (CDx) offerings and support several strategic initiatives including
- Introducing scaled, plug-and-play products for a range of indications and tasks, including tumor microenvironment and biomarker profiling.
- Continued expansion in the US with additional employees and support for US partners.
- Joint development of basic models and biopharmaceutical product offerings with Mayo Clinic.
“2024 was a pivotal year for us, which included important strategic collaboration with Bayer and the launch of our first foundation model, RudolfV,” said Viktor MatyasCEO and co-founder of Aignostics. “With RudolfV we have gained the ability to quickly develop cost-effective algorithms that can be transferred to the real world. With this new round of funding, we are turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology.”
Information about Aignostics
Aignostics is an artificial intelligence (AI) company that transforms complex multimodal pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies and rigorous science, Aignostics develops world-class products and services for the next generation of precision medicine. Through collaboration with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials and CDx development. The company Aignostics, founded in 2018, is a spin-off from Charité Berlin, one of the largest and most renowned university hospitals in the world. Aignostics is funded by leading investors and has offices in Berlin and New York.
Further information at: www.aignostics.com
Follow us on LinkedIn: www.linkedin.com/company/aignostics
Information about ATHOS
ATHOS is a single-family office specializing in the health and life sciences sectors, supporting entrepreneurs who are positively impacting health and well-being. ATHOS is known to the broader public as a long-term majority investor in BioNTech and remains committed to promoting medical innovation and building groundbreaking companies.
Information about HTGF – High-Tech Gründerfonds
The HTGF is one of the leading and most active early-stage investors in Germany and Europe and finances start-ups in the areas of deep tech, industrial tech, climate tech, digital tech, life sciences and chemistry. With its experienced investment team, the HTGF supports start-ups in all phases of their development into international market leaders. The HTGF invests in the pre-seed and seed phases and is significantly involved in further financing rounds, since 2024 with the HTGF Opportunity growth fund. The HTGF manages more than 2 billion euros through its funds. Since its founding in 2005, the HTGF has financed more than 750 start-ups and successfully sold shares in more than 180 companies. The Federal Ministry of Economics and Climate Protection, KfW Capital and numerous companies are involved in the HTGF seed funds. Investors in the HTGF Opportunity growth fund include the ERP special fund and KfW with funds from the future fund.
Further information at: www.htgf.de
Follow us on LinkedIn: www.linkedin.com/company/high-tech-gruenderfonds
Contact
Lisa Zheng
[email protected]
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
